从传统Pharma到全球创新药企,东阳光药华丽转身

医药魔方
24 Jun

—各奖项申报陆续启动,欢迎关注—近两年,中国传统药企的创新转型浪潮迎来关键质变。当恒瑞医药以创新药收入撑起业绩“半壁江山”,向业界有力地证明了创新转型的价值之际,头顶“流感巨头”标签的东阳光药业,正通过一场筹备已久的港交所IPO(6月11日递交申请),悄然拉开其转型大幕。刻板印象之外,这家企业凭借二十余年的深厚研发积淀走向IPO的历程,正徐徐勾勒出传统Pharma向创新药企蜕变的完整图景。创新转型...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10